Prognostic variables that may influence treatment decisions for cardiac sarcoidosis

• Age >50 years
• Left ventricular ejection fraction <40%
• New York Heart Association Functional Class III or IV
• Increased left ventricular end-diastolic diameter
• Late gadolinium enhancement on cardiac magnetic resonance imaging
• Ventricular tachycardia
• Cardiac inflammation identified by fluorodeoxyglucose positron emission tomography scan
• Echocardiographic evidence of abnormal global longitudinal strain
• Interventricular septal thinning
• Elevated troponin or brain natriuretic peptide

Features found to be associated with increased risk for morbidity or mortality from cardiac sarcoidosis [150159].